EUVIMEDEUVIMED entdecken
Crossref

The Broader Economic Value of Treatment for Diabetic Macular Edema

Karen Mulligan iD, Jaehong Kim, Bryan Tysinger, Jill Blim, Geoffrey Emerson, Philip J Ferrone, Judy E Kim, Seth Seabury, Paul Hahn

Diabetes Care · 2023

DOI: 10.2337/dc22-2527 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, 2023. Verfasst von Karen Mulligan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sol Price School of Public Policy, University of Southern California, Los Angeles, CA. Hauptthemen laut MEDLINE: Macular Edema, Diabetic Retinopathy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: American Society of Retina Specialists.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To simulate economic outcomes for individuals with diabetic macular edema (DME) and estimate the economic value of direct and indirect benefits associated with DME treatment. RESEARCH DESIGN AND METHODS Our study pairs individual and cohort analyses to demonstrate the value of treatment for DME. We used a microsimulation model to simulate self-reported vision (SRV) and economic outcomes for individuals with DME. Four scenarios derived from clinical trial data were simulated and compared for a lifetime horizon: untreated, anti-VEGF therapy, laser, and steroid. To quantify the relative magnitude of costs and benefits of DME treatment in the U.S., we used a cohort-level analysis based on real-world treatment parameters derived from published data. RESULTS In the model, excellent/good SRV roughly corresponded to 20/40 or better visual acuity. A representative 51-year-old treated for DME would spend 30–35% additional years with excellent/good SRV and 29–32% fewer years with fair/poor SRV relative to being untreated. A treated individual would experience 4–5% greater life expectancy and 9–13% more quality-adjusted life-years. Indirect benefits from treatment included 6–9% more years working, 12–19% greater lifetime earnings, and 8–16% fewer years with disability. For the U.S. DME cohort (1.1. million people), total direct benefit was $63.0 billion over 20 years, and total indirect benefit was $4.8 billion. Net value (benefit − cost) of treatment ranged from $28.1 billion to $52.8 billion. CONCLUSIONS Treatment for DME provides economic value to patients and society through improved vision, life expectancy, and quality of life and indirectly through improved employment and disability outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macular EdemaDiabetic RetinopathyHumansMiddle AgedMaleFemaleCost-Benefit AnalysisQuality-Adjusted Life YearsVisual AcuityAged

Autor:innen und Institutionen

  • Sol Price School of Public Policy, University of Southern California, Los Angeles, CA.
  • Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, CA.
  • School of Pharmacy, University of Southern California, Los Angeles, CA.
  • American Society of Retina Specialists, Chicago, IL.
  • Retina Consultants of Minnesota, Edina, MN.
  • Vitreoretinal Consultants, Great Neck, NY.

ORCID-Profile: Karen Mulligan

Förderung

  • American Society of Retina Specialists

Zitieren

APA

Mulligan, K., Kim, J., Tysinger, B., Blim, J., Emerson, G., Ferrone, P. J., Kim, J. E., Seabury, S., & Hahn, P. (2023). The Broader Economic Value of Treatment for Diabetic Macular Edema. Diabetes Care. https://doi.org/10.2337/dc22-2527

Vancouver

Mulligan K, Kim J, Tysinger B, Blim J, Emerson G, Ferrone PJ, et al. The Broader Economic Value of Treatment for Diabetic Macular Edema. Diabetes Care. 2023. doi:10.2337/dc22-2527

BibTeX
@article{Mulligan2023,
  author = {Mulligan, Karen and Kim, Jaehong and Tysinger, Bryan and Blim, Jill and Emerson, Geoffrey and Ferrone, Philip J and Kim, Judy E and Seabury, Seth and Hahn, Paul},
  title = {The Broader Economic Value of Treatment for Diabetic Macular Edema},
  journal = {Diabetes Care},
  year = {2023},
  doi = {10.2337/dc22-2527}
}
Kostenlos starten →